

## **Current status and future directions in unresectable stage III non-small cell lung cancer**

Esperanza Arriola Arellano, Verónica Díaz Díaz, Joaquín José Cabrera Rodríguez

Corresponding author:

Joaquín José Cabrera Rodríguez

*Department of Radiation Oncology. University Hospital of Badajoz. 06080. Badajoz. Spain*

---

Handling editor:

Michal Heger

*Department of Pharmaceutics, Utrecht University, the Netherlands*

*Department of Pharmaceutics, Jiaying University Medical College, Zhejiang, China*

Review timeline:

Received: 08 June, 2020

Editorial decision: 22 August, 2020

Revision received: 10 September, 2020

Editorial decision: 15 September, 2020

Revision received: 09 October, 2020

Editorial decision: 09 October, 2020

Published online: 29 October, 2020

---

1<sup>st</sup> Editorial decision

22-Aug-2020

Ref.: Ms. No. JCTRes-D-20-00053

Current status and future directions in inoperable stage III non-small cell lung cancer.

Journal of Clinical and Translational Research

Dear author(s),

Reviewers have submitted their critical appraisal of your paper. The reviewers' comments are appended below. Based on their comments and evaluation by the editorial board, your work was FOUND SUITABLE FOR PUBLICATION AFTER MINOR REVISION.

If you decide to revise the work, please itemize the reviewers' comments and provide a point-by-point response to every comment. An exemplary rebuttal letter can be found on at <http://www.jctres.com/en/author-guidelines/> under "Manuscript preparation." Also, please use the track changes function in the original document so that the reviewers can easily verify your responses.

Your revision is due by Sep 21, 2020.

To submit a revision, go to <https://www.editorialmanager.com/jctres/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Yours sincerely,

Felipe Couñago  
Editorial Board Member  
Journal of Clinical and Translational Research

Reviewers' comments:

Reviewer 2: The terms inoperable and unresectable are being used indistinctively during the article, including the title. In my opinion, the article is referred to the unresectable patients /locally advanced lung cancer, not specifically the inoperable subset stage IIIA cancer.

---

Authors' response

Joaquín J. Cabrera Rodríguez.  
Department of Radiation Oncology.  
Universitary Hospital of Badajoz  
Avenida de Elvas, s/n  
06080 Badajoz  
SPAIN.  
T. +34924267970 (48542)  
[Joaquin.cabrera@salud-juntaex.es](mailto:Joaquin.cabrera@salud-juntaex.es)

Badajoz, 10 september 2020.

Re: Ms. No. JCTRes-D-20-00053

Dear Editor:

Thank you for giving us an opportunity to resubmit a revised version of our manuscript entitled "Current status and future directions in unresectable stage III non-small cell lung cancer". We have addressed all comments of the reviewers using the track changes function in Word. Moreover, every modification or rebuttal of the reviewer's comments is detailed per comment below in red italics. We are grateful for the useful comments of the reviewers, as a result of which the paper has been improved. On behalf of the authors, kindest regards,  
Joaquín J. Cabrera.

---

**Reviewers' comments:**

Reviewer #2: The terms inoperable and unresectable are being used indistinctively during the article, including the title. In my opinion, the article is referred to the unresectable patients /locally advanced lung cancer, not specifically the inoperable subset stage IIIA cancer.

*Errors in the application of inoperable and unresectable terms have been corrected in the title, cover letter and manuscript, as suggested by the reviewer.*

---

2<sup>nd</sup> Editorial decision  
15-Sept-2020

Ref.: Ms. No. JCTRes-D-20-00053R1

Current status and future directions in unresectable stage III non-small cell lung cancer.

Journal of Clinical and Translational Research

Dear author(s),

Reviewers have submitted their critical appraisal of your paper. The reviewers' comments are appended below. Based on their comments and evaluation by the editorial board, your work was FOUND SUITABLE FOR PUBLICATION AFTER MINOR REVISION.

If you decide to revise the work, please itemize the reviewers' comments and provide a point-by-point response to every comment. An exemplary rebuttal letter can be found on at <http://www.jctres.com/en/author-guidelines/> under "Manuscript preparation." Also, please use the track changes function in the original document so that the reviewers can easily verify your responses.

Your revision is due by Oct 15, 2020.

To submit a revision, go to <https://www.editorialmanager.com/jctres/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Yours sincerely,

Michal Heger  
Editor-in-Chief  
Journal of Clinical and Translational Research

Reviewers' comments:

Dear authors, I have carefully read through your manuscript and, before I can accept the manuscript for submission, I kindly ask you to carefully and thoroughly proofread the paper and eliminate the numerous grammatical and spelling errors. This is in line with our journal policy: <https://www.jctres.com/en/author-guidelines/>. Please inform me if you need native speaker assistance, as we have several people in our organization who could provide the service for a fee. Thank you and kindest regards, Michal Heger, editor in chief.

---

Authors' response

Joaquín J. Cabrera Rodríguez.  
Department of Radiation Oncology.  
Universitary Hospital of Badajoz  
Avenida de Elvas, s/n  
06080 Badajoz  
SPAIN.  
T. +34924267970 (48542)  
[Joaquin.cabrera@salud-juntaex.es](mailto:Joaquin.cabrera@salud-juntaex.es)  
Badajoz, 9 October 2020.

Re: Ms. No. JCTRes-D-20-00053

Dear Editor:

Thank you for giving us an opportunity to resubmit a revised version of our manuscript entitled “Current status and future directions in unresectable stage III non-small cell lung cancer”.

We have addressed all comments of the reviewers using the track changes function in Word. Moreover, every modification or rebuttal of the reviewer’s comments is detailed per comment below in red italics.

We are grateful for the useful comments of the reviewers, as a result of which the paper has been improved.

On behalf of the authors, kindest regards,  
Joaquín J. Cabrera.

**Reviewers' comments:**

Reviewer #2: The terms inoperable and unresectable are being used indistinctively during the article, including the title. In my opinion, the article is referred to the unresectable patients /locally advanced lung cancer, not specifically the inoperable subset stage IIIA cancer. *Errors in the application of inoperable and unresectable terms have been corrected in the title, cover letter and manuscript, as suggested by the reviewer.*

**Reviewers' comments:**

Dear authors, I have carefully read through your manuscript and, before I can accept the manuscript for submission, I kindly ask you to carefully and thoroughly proofread the paper and eliminate the numerous grammatical and spelling errors. *The text of the article has been revised by a native-English speaker specialized in medical language. All grammatical mistakes have been fully corrected.*

---

3<sup>rd</sup> Editorial decision  
9-Oct-2020

Ref.: Ms. No. JCTRes-D-20-00053R2  
Current status and future directions in unresectable stage III non-small cell lung cancer.  
Journal of Clinical and Translational Research

Dear authors,

I am pleased to inform you that your manuscript has been accepted for publication in the Journal of Clinical and Translational Research.

You will receive the proofs of your article shortly, which we kindly ask you to thoroughly review for any errors.

Thank you for submitting your work to JCTR.

Kindest regards,

Journal of Clinical and Translational Research  
Peer review process file 06.2020S4.006



Michal Heger  
Editor-in-Chief  
Journal of Clinical and Translational Research

Comments from the editors and reviewers: